Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 12/20 | 0.56 |
| ▸ | PGR | P06401 | 11/20 | 0.56 |
| ▸ | NR3C2 | P08235 | 11/20 | 0.56 |
| ▸ | AR | P10275 | 11/20 | 0.56 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.45 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | CKS1B | P61024 | 1/20 | 0.41 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.41 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.41 |
| ▸ | PLA2G7 | Q13093 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6090068 | 0.85 | NR3C1 (0.56) | NR3C1PGRNR3C2ARIMPDH2 | |
| SCHEMBL6091033 | 0.84 | NR3C2 (0.57) | NR3C1PGRNR3C2ARIMPDH2 | |
| SCHEMBL6091758 | 0.78 | NR3C1 (0.49) | NR3C1PGRNR3C2ARIMPDH2 | |
| SCHEMBL6090269 | 0.77 | NR3C1 (0.58) | NR3C1PGRNR3C2ARPARP14 | |
| SCHEMBL6090518 | 0.76 | NR3C1 (0.72) | NR3C1PGRNR3C2ARKEAP1 | |
| SCHEMBL6088923 | 0.75 | NR3C2 (0.53) | NR3C1PGRNR3C2ARIMPDH2 | |
| SCHEMBL6091846 | 0.75 | NR3C1 (0.48) | NR3C1PGRNR3C2ARPARP14 | |
| SCHEMBL6090407 | 0.75 | NR3C1 (0.62) | NR3C1PGRNR3C2ARPLA2G7 | |
| SCHEMBL6090942 | 0.74 | NR3C1 (0.55) | NR3C1PGRNR3C2ARKEAP1 | |
| SCHEMBL6089321 | 0.74 | NR3C1 (0.54) | NR3C1PGRNR3C2ARPARP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060235222-A1 | Indole-derivative modulators of steroid hormone nuclear receptors | ELI LILLY AND COMPANY (US) | 2006-10-19 | — | — | US | disclosed |
| EP-1597254-A1 | INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | Eli Lilly and Company (US) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004067529-A1 | INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | ELI LILLY AND COMPANY (US) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235222-A1 | Indole-derivative modulators of steroid hormone nuclear receptors | NR3C2, NR5A1, MC2R | NR3C1 4/4885PGR 148/4885NR3C2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.